Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2004 Filed May 5, 2004 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,000 | $14.81 | $118,500.00 |
DisclosureSEC source: 0001179110-04-009715 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| February 03, 2004 Filed Feb 4, 2004 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $14.81 | $0.00 |
DisclosureSEC source: 0001179110-04-002473 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,120 Underlying: Common Stock · 7,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options, split between incentive and non-qualified stock options, vest 20% on 4/5/01 the first anniversary date of the grant, with the balance vesting quarterly over the next four years. Read SEC document |
| February 03, 2004 Filed Feb 4, 2004 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $56.95 | $39,865.00 |
DisclosureSEC source: 0001179110-04-002473 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,081 F1 · balance_after: All shares and dollar amounts reflect two-for-one stock splits in February 2001 and March 2002. Read SEC document |
| February 03, 2004 Filed Feb 4, 2004 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $56.90 | $28,450.00 |
DisclosureSEC source: 0001179110-04-002473 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,781 Read SEC document |
| February 03, 2004 Filed Feb 4, 2004 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,800 | $56.89 | $329,962.00 |
DisclosureSEC source: 0001179110-04-002473 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,281 Read SEC document |
| February 03, 2004 Filed Feb 4, 2004 23:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,000 | $14.81 | $103,687.50 |
DisclosureSEC source: 0001179110-04-002473 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2004 Filed Jan 30, 2004 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 148,363 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001179110-04-002091 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,363 Underlying: Common Stock · 148,363 shares Expires 2014-01-28 F2 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. Read SEC document |
| January 28, 2004 Filed Jan 30, 2004 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 1,637 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001179110-04-002091 · edgar.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637 Underlying: Common Stock · 1,637 shares Expires 2014-01-28 F2 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,356 | $0.00 Strike: $14.16 | $0.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · derivative · entry 14 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,780 Underlying: Common Stock · 1,356 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,644 | $0.00 Strike: $14.16 | $0.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · derivative · entry 13 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220 Underlying: Common Stock · 5,644 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · derivative · entry 12 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,500 shares Expires 2009-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · derivative · entry 11 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2008-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,144 | $63.21 | $261,942.24 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 10 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,012 F1 · balance_after: All shares and dollar amounts reflect two-for-one stock splits in February 2001 and March 2002. F2 · balance_after: Amount of Securities Beneficially Owned at End of Month (Table 1, Col5) includes 647 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on 06/30/03. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,500 | $63.30 | $94,950.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 9 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,156 Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,644 | $14.16 | $79,898.16 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 8 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,356 | $63.21 | $85,712.76 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,012 Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,356 | $14.16 | $19,195.94 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $63.30 | $158,250.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,012 Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,500 | $14.59 | $36,484.50 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $63.30 | $63,300.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,012 Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $63.55 | $31,775.00 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,012 Read SEC document |
| August 07, 2003 Filed Aug 11, 2003 21:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,500 | $5.72 | $8,578.20 |
DisclosureSEC source: 0001179110-03-005324 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2003 Filed Aug 4, 2003 16:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $69.99 | $0.00 |
DisclosureSEC source: 0001179110-03-004744 · edgar.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2013-07-29 F2 · derivative.exercise_date: Options vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning 7/30/04. The option will be fully vested by 7/30/08. Read SEC document |
| June 30, 2003 Filed Aug 4, 2003 16:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | OtherCommon Stock | 647 | $29.66 | $19,187.76 |
DisclosureSEC source: 0001179110-03-004744 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,365 F1 · kind: Purchase under Section 423 Plan exempt from Section 16(b)under Rule 16(b)-3(c). F3 · balance_after: All shares and dollar amounts reflect two-for-one stock splits in February 2001 and March 2002. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.